Drug
Fenretinide clinical trials
Also written McN-R-1967, ST-001 and N-(4-hydroxyphenyl)retinamide.
- studies test it
- 45
- open now
- 2
- in phase 3
- 7
- first study started
- 1993
Keep track of what changes. Save the Fenretinide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Other names
Studies by the year they started
44 studies that test it; most in 2000 (5)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1994 | 1 |
| 1995 | 1 |
| 1996 | 1 |
| 1997 | 2 |
| 1998 | 3 |
| 1999 | 1 |
| 2000 | 5 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 22
- Phase 3
- 7
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 36
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (5) · South Plains Oncology Consortium (4) · Laurent Pharmaceuticals Inc. (3) · Island Pharmaceuticals (2) · Eastern Cooperative Oncology Group (2) · California Cancer Consortium (2) · Barbara Ann Karmanos Cancer Institute (2)
Often tested with
Tested in the same studies.
Tamoxifen (2) · Cisplatin (2) · Paclitaxel (2) · Tretinoin (1) · Ketoconazole (1) · Vincristine (1) · Lonafarnib (1) · Rituximab (1)
Studies
Open first, then newest update. How each study uses Fenretinide is read from its arms, and is right about nine times in ten.
Testing it · 45
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingPhase 1SciTech Development, Inc.NCT04234048Written as Fenretinide
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung CancerRecruitingPhase 1SciTech Development, Inc.NCT06922539Written as Fenretinide
- N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant NeuroblastomaCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT00646230Written as fenretinide
- Study of LAU-7b for the Treatment of Long COVID in AdultsCompletedPhase 2/3Laurent Pharmaceuticals Inc.NCT05999435Written as LAU-7b for 3 cycles
- Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in AdultsTerminatedPhase 2/3Laurent Pharmaceuticals Inc.NCT04417257Written as LAU-7b
- Study to Examine the Effects of Oral FenretinideCompletedPhase 2Island PharmaceuticalsNCT06528457Written as ISLA101
- A Study to Evaluate the Safety of Fenretinide in Healthy VolunteersCompletedPhase 1Island PharmaceuticalsNCT06181760Written as Fenretinide
- Study of LAU-7b in the Treatment of Cystic Fibrosis in AdultsCompletedPhase 2Laurent Pharmaceuticals Inc.NCT03265288Written as LAU-7b
- Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus SyndromeCompletedPhase 2Eastern Cooperative Oncology GroupNCT00003601Written as fenretinide
- Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHLTerminatedPhase 1South Plains Oncology ConsortiumNCT01187810Written as Fenretinide
- Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant NeuroblastomaTerminatedPhase 1South Plains Oncology ConsortiumNCT02163356Written as Fenretinide/LXS Oral Powder
- Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed MalignanciesTerminatedPhase 1South Plains Oncology ConsortiumNCT01553071Written as Fenretinide (4-HPR) plus Intravenous Safingol
- A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With ObesitySuspendedPhase 2University of California, San DiegoNCT00546455Written as Fenretinide
- Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian CancerTerminatedPhase 1/2South Plains Oncology ConsortiumNCT01535157Written as Fenretinide/LXS + Ketoconazole
- Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell LymphomasStatus unknownPhase 2CerRx, Inc.NCT02495415Written as Fenretinide
- 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedPhase 1M.D. Anderson Cancer CenterNCT00102635Written as Fenretinide (4-HPR)
- Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder CancerCompletedPhase 3M.D. Anderson Cancer CenterNCT00004154Written as Fenretinide
- Fenretinide in Healthy Young Women at Genetic and Familial RiskTerminatedPhase 3European Institute of OncologyNCT01479192Written as Fenretinide
- Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT00006471Written as Fenretinide
- Fenretinide in Treating Patients With Cervical NeoplasiaCompletedPhase 3M.D. Anderson Cancer CenterNCT00003075Written as Fenretinide
Codes
What other systems call Fenretinide · ClinicalTrials.gg INT008581
- MeSH (NLM) D017313FenretinideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 187EJ7QEXLFENRETINIDEConfirmed FDA, NLM, Wikidata
- RxNorm 24870One source Wikidata
- Wikidata Q5443576fenretinideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1098FenretinideOne source FDA
- DrugBank DB05076One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017313 | Fenretinide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 187EJ7QEXL | FENRETINIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 24870 | — | One source Wikidata |
| Wikidata | Q5443576 | fenretinide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1098 | Fenretinide | One source FDA |
| DrugBank | DB05076 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.